Ascletis PharmaASCLF -4.00%38 3-1 Month Momentum % is -35.71% as of Jul. 12, 2026. GuruFocus rates ASCLF with a GF Score™ of 38/100 and a GF Value™ of $0.02 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,389 Biotechnology companies, Ascletis Pharma ranks worse than 93.66% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-07-12), Ascletis Pharma's 3-1 Month Momentum % is -35.71%.
The industry rank for Ascletis Pharma's 3-1 Month Momentum % or its related term are showing as below:
ASCLF's 3-1 Month Momentum % is ranked worse than 93.66% of 1389
companies
in the Biotechnology industry
Industry Median: -11.38
vs ASCLF: -35.71
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Ascletis Pharma 3-1 Month Momentum % Related Terms
ASCLF vs VRTX, REGN, ALNY: 3-1 Month Momentum % Comparison
For the Biotechnology subindustry, Ascletis Pharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascletis Pharma 3-1 Month Momentum % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ascletis Pharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Ascletis Pharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascletis Pharma (ASCLF) has a 3-1 Month Momentum % of -35.71% as of Jul. 12, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ascletis Pharma and its competitors. According to the industry distribution chart, Ascletis Pharma ranks #1301 out of 1389 companies in the Biotechnology industry, placing it in the top 93.7%.
Is Ascletis Pharma's 3-1 Month Momentum % too high?
Ascletis Pharma's current 3-1 Month Momentum % is -35.71%. Based on the distribution chart, Ascletis Pharma ranks #1301 out of 1389 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Ascletis Pharma has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ascletis Pharma's 3-1 Month Momentum % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascletis Pharma ranks #1301 out of 1389 companies for 3-1 Month Momentum %. This places Ascletis Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Biotechnology company?
A good 3-1 Month Momentum % depends on the Biotechnology industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Ascletis Pharma and its competitors. Ascletis Pharma's current 3-1 Month Momentum % is -35.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascletis Pharma stock overvalued right now?
Based on GuruFocus' analysis, Ascletis Pharma (ASCLF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.02, compared to a current price of $1.44 — trading 7100% above its estimated fair value. The current 3-1 Month Momentum % is -35.71%. Ascletis Pharma's overall GF Score™ is 38/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Ascletis Pharma (ASCLF), the current 3-1 Month Momentum % is -35.71% as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascletis Pharma (ASCLF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascletis Pharma stock appears to be overvalued.
The current stock price of $1.44 is trading 7100% above its estimated GF Value™ of $0.02.
GuruFocus considers Ascletis Pharma to be Significantly Overvalued.
Key valuation signals for ASCLF:
3-1 Month Momentum %: -35.71%
GF Value™: $0.02 vs. price of $1.44 (7100% above fair value)
No single metric tells the full story. See the ASCLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascletis Pharma Inc is an investment holding company. Along with its subsidiaries, it is engaged in the research and development, production, marketing, and sale of pharmaceutical products. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
38GF Score
Get the complete analysis for ASCLF
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASCLF has been successfully added to your 